Apologies. Let us clarify. They paid for the "valuation".
"...Impact Biomedical’s ownership of a suite of antiviral and medical technologies has been valued at $382 million by Destum Partners..."
To your point, the $50MM "purchase price" is not cash, it is the Company's own equity. It could have been any number they picked out of the proverbial hat. Simplified...there's zero material basis for the number at this point.
Lest you forget, these transactions are all occurring in a vacuum, it's just one of Chan's companies moving capital into another one. There's little, if any, actual outside business being done here. In our humble opinion, even the capital being used is the same, last in first out.
We just have to hope that someday, somewhere over the rainbow, bluebirds will fly.
Market Data 
Markets 
AI
